ArticleCardiovascular diabetology2026
Independent association of leg-height ratio with 15 cardiometabolic diseases.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe association between adult height and coronary artery disease (CAD) was established a decade ago. Accumulating evidence has since linked adult height to a variety of cardiometabolic diseases (CMD). As waist-hip ratio (WHR) has become an increasingly important independent risk factor in addition to body mass index, we aim to assess whether leg-height ratio (LHR) could also be a risk factor independent of overall height.
methodsLHR was defined as the ratio of leg length to standing height and further adjusted for overall height by regression. Using data from UK Biobank, we first performed genome-wide association study (GWAS) of LHR and height, then assessed their associations with 15 major CMD at phenotypic and genetic levels. Mediation and colocalization analyses were conducted to identify mediators and shared variants.
resultsWe identified 747 genome-wide significant variants of LHR after stepwise conditional and joint analysis. SNP-based heritability was estimated at 24% for LHR, versus 47% for height. A low LHR (bottom 20%) was associated with a substantially higher risk of CAD than a medium (middle 60%) or high (top 20%) LHR, regardless of the height category. This pattern is pronounced for type 2 diabetes (T2D), where tall individuals with low LHR exhibit higher risk (HR = 1.39 [1.29−1.49], P = 2.7 × 10–20) than individuals of short or medium height with higher LHR. Lipids (especially high-density lipoprotein cholesterol) primarily mediated the protective effect of LHR on CMD, whereas inflammatory markers (especially neutrophils) mainly mediated the effect of height on CMD. Colocalization analyses revealed LHR-specific variants shared with CMD, including notable colocalization with T2D at the JAZF1 locus.
conclusionsLHR has independent and differential effects on a suite of CMD traits. The protective association between LHR and CMD is mainly mediated by lipids, and genes shared between LHR and these outcomes are predominantly enriched in development and differentiation of skeletal and embryonic tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.